Introduction
============

Metabolic syndrome (MS) refers to a cluster of features namely central obesity, insulin resistance, dyslipidemia, and hypertension ([@b21]). Numerous studies have been conducted worldwide on the prevalence of MS across different ethnic groups ([@b18]; [@b2]; [@b29]; [@b15]), the correlation between the components of the syndrome ([@b14]; [@b4]) and increased incidence of cardiovascular diseases (CVD) ([@b3]; [@b7]). Asian Indians have long been considered to be a "high-risk population" for both MS and CVD, which has instigated a number of studies on Indians living in India ([@b22]; [@b19]) and abroad ([@b13]; [@b25]; [@b23]).

The National Cholesterol Education Program--Adult Treatment Panel III ([@b20]) and World Health Organization ([@b27]) have laid down guidelines to define MS and both definitions have been widely applied to different populations under study. While Insulin resistance has been the pivotal feature in the WHO criteria, waist circumference (WC) rather than body mass index (BMI) has been the differentiating aspect of MS definition in the ATP-III panel. The International Diabetes Federation (IDF) proposed a slight modification in the ATP-III definition in 2005 ([@b1]) where presence of abdominal obesity was considered mandatory for MS diagnosis. The American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI) supports the widely used ATP-III criteria except for a lowering of threshold for impaired fasting glucose (IFG) from 110 to 100 mg/dL ([@b11]) as recommended by IDF. In spite of the various criteria devised for MS diagnosis, most studies agree that the prevalence of MS in Asian Indians is underrepresented when ATP-III or WHO criteria are employed, considering the high propensity of this ethnic group to develop MS and its various co-morbidities ([@b19]). It is well known that Asian Indians have a smaller build and excess body fat with predominant abdominal adiposity as compared with Caucasians. To this effect, the WHO has recognized the need for a population-specific modification of anthropometric measures. The recommended lower BMI cut-off for defining 'overweight' in Asian Indians is 23 kg/m^2^ ([@b28]), modified WC measures is ≥94 cm and ≥80 cm ([@b19]) and a waist--hip ratio (WHR) of 0.89 and 0.81 for men and women, respectively ([@b24]). These modified cut-offs have been applied when studying Asian Indians by several investigators ([@b19]; Tan et al 2005; [@b26]; [@b12]).

In this context, the aim of this study was to assess the prevalence of MS as defined by the standard ATP-III and WHO criteria and the modified criteria, and to look for differences between the various components constituting MS in subjects with and without the syndrome in a high-risk cohort of families with premature onset of coronary artery disease (CAD).

Materials and methods
=====================

Subjects
--------

The current study has been conducted on a cohort enrolled into the Indian Atherosclerosis Research Study (IARS), by the Thrombosis Research Institute-India (TRI-India). IARS is an on-going family based genetic epidemiological study, with an aim to investigate the genetic factors associated with CAD along with their interaction with traditional and novel risk factors in a cohort of Asian Indian population in their home country. The IARS families were enrolled from two cities, Bangalore in South India and Mumbai in Western India from March 2004 -- July 2005. Subjects were ascertained through a proband (males ≤60 years; females ≤65 years at onset of CAD) admitted to Narayana Hrudayalaya, a multispecialty hospital and other cardiac care hospitals in Bangalore and to the Asian Heart Institute in Mumbai for undergoing treatment for CAD and its complications. Only probands with a positive family history of CAD were enrolled into the study. A detailed pedigree of the families of each proband was drawn and affected and unaffected family members over 18 years age were subsequently enrolled into the study. None of the participants had concomitant or past major illness. In total, five hundred and thirty one families comprising of 2316 individuals, 1355 males and 961 females were enrolled, with a mean of 4.37 individuals per family.

A detailed case record form containing information on demographics, anthropometry and medical history of diabetes, hypertension and CVD was recorded for all the participants. General physical examination along with vital parameters was performed. Relevant information was obtained by personal interviews and through medical records available with the subjects and/or from the hospital records. Prevalence of diabetes (DM), hypertension (HTN), and CVD was ascertained based on self-report of physician's diagnosis and/or use of prescription medications along with medical records of therapeutics. Additional information on diabetic status was obtained from IFG levels. All participants gave their written informed consent to participate in the study that was approved by the local Ethics Committee.

Clinical profile and anthropometrics
------------------------------------

Height, weight, waist and hip circumference and blood pressure (BP) was measured for each participant. BMI was calculated as a ratio of weight in Kg to the height in meter^2^.

Laboratory assays
-----------------

Venous blood was collected in evacuated tubes after an overnight fast of 12 to 14 hours (Vacuette^®^, Greiner Bio-One GmbH, Vienna, Austria). Serum, EDTA, and citrate plasma samples were separated by centrifugation within 2 hours of sampling and aliquots were preserved at −80 °C until analysis. Samples from Mumbai were stored at −20 °C until dispatch to TRI labs in Bangalore for analysis. Fasting venous blood sugar was assayed using a Glucometer (Bayer Diagnostics, Newbury, UK). Serum triglyceride (TG) was estimated using reagents, standards and controls from Randox Laboratories Ltd., Antrim, UK. Estimation of high density lipoprotein cholesterol (HDL-C) levels was carried out by the phosphotungstate method using precipitating agents and buffer from Bayer Diagnostics, control from Randox Labs and standards from Dade-Behring Limited, UK. All lipid assays were carried out on Cobas-Fara II Clinical Chemistry Auto analyzer (F. Hoffman La Roche Ltd., Basel, Switzerland).

Candidate metabolic syndrome definitions
----------------------------------------

Prevalence of metabolic syndrome in the cohort was assessed on the basis of the following criteria:

1.  A\) The 2001 NCEP--ATP-III guidelines, wherein presence of any three of the following traits in the same individual would meet the criteria for MS:

    1.  Abdominal obesity as defined by WC \>102 cm (40 in) in men and \>88 cm (35 in) in women;

    2.  Serum TG ≥150 mg/dL (1.7 mml/L);

    3.  HDL-C ≤40 mg/dl in men (1.03 mmol/L) and ≤50 mg/dl (1.29mmol/L) in women;

    4.  Blood pressure of ≥130/85 mmHg

    5.  Fasting blood glucose level of ≥110 mg/dL (6.1 mmol/L).

2.  B\) The WHO criteria emphasized insulin resistance, identified by type 2 diabetes mellitus or an impaired fasting glucose of ≥110 mg/dl, in addition to the following features:

    1.  WHR of \>0.9 in men, \>0.85 in women or a BMI \>30 Kg/m^2^.

    2.  Hypertriglyceridemia with TG\>150mg/dl;

    3.  HDL-C \<35 mg/dl for men and \<39 mg/dl for women;

    4.  High BP \>140/90 mm Hg or documented evidence of anti-hypertensive therapy.

    Presence of Microalbuminuria was not assessed in our cohort.

3.  C\) IDF (International Diabetic Federation 2005): Abdominal obesity as defined by WC ≥94 cm for men and ≥80 cm is a mandatory feature of this definition and is specific to Asians. In addition, any of the two features as defined in ATP-III constitute MS by this criteria. IFG cut-off level was ≥100 mg/dL.

4.  D\) Modified ATP-III-1 \[MS1\]: WC cutoffs ≥90 cm for men and ≥80 cm for women. Criteria from 2 to 5 were unchanged as per the NCEP ATP-III description above.

5.  E\) Modified ATP-III-2 \[MS2\]: BMI cutoff at \>23 Kg/m^2^ in addition to the criteria used in MS1.

6.  F\) Modified WHO \[MS3\]: The definitions were same as for the WHO criteria except for WHR of ≥0.89 in males and ≥0.81 in females and a BMI \>23 kg/m.^2^

Statistical analysis
--------------------

Results are expressed as mean ± standard deviation for the continuous variables. Chi Square test with Yates correction was employed to analyze the differences in the prevalence of MS as identified using candidate definitions. Pearson's partial correlation was carried out to investigate the inter-relationship amongst the various MS components after adjustment for gender and age. Values were log-transformed to normalize distribution. Student T-test was employed to evaluate the difference in means levels of various markers between those with and without MS. For statistical comparison of the continuous variables, ANCOVA was used with adjustment for age, gender, BMI and smoking. Generalized estimating equation (GEE) was applied to study the significant trait differences between MS and non-MS subjects using STATA version 9.0 software. Since observations within families are not independent but correlated, GEE adjusts for the effect of familial relationship and subsequently looks for significant relationship between traits in the MS and non-MS groups. Families were assumed to have binomial distribution for discrete vairables and Gaussian distribution for continuous variables under the assumption of unstructured correlation within families for any of the analysed traits. A nominal two-sided p-value \<0.05 was considered significant. All statistical tests were computed on SPSS v10 software.

Results
=======

Standard candidate definitions (ATP-III, WHO, IDF) and various adaptations therein (MS1, MS2, MS3) were applied to 2316 individuals enrolled into the IARS. Prevalence of MS based on various definitions is presented in [Table 1](#tbl1){ref-type="table"}. The number of people diagnosed with MS by the ATP-III criteria (N = 933) was significantly higher than by the WHO criteria (N = 708; p \< 0.0001). Among the modified ATP-III criteria, MS2 that included revised cut offs for WC and BMI identified maximum MS subjects (N = 1333). The IDF criteria identified similar proportion of people with MS (N = 809; 34.9%) as the modified WHO criteria (MS3) (N = 792; 34.2%). Maximum gain in MS diagnosis was observed in the modified ATP-III group (MS2) (17.3%) when compared with standard ATP-III guidelines. Analyses of percentage prevalence gain of MS by the modified ATP-III criteria (MS1, MS2) and WHO criteria (MS3) revealed significant gain (N = 400) by MS2 over MS3 (p = 0.0056) criteria.

###### 

Prevalence of metabolic syndrome (MS) according to different definition criteria

  MS Definition   N      Percent
  --------------- ------ ---------
  ATP-III         933    40.3
  WHO             708    30.6
  IDF             809    34.9
  MS1             1187   51.3
  MS2             1333   57.6
  MS3             792    34.2

**Abbreviations:** ATP-III, Adult Treatment Plan 111; WHO, World Health Organization; IDF, International Diabetic Foundation; MS1, ATP-III definition modified with respect to WC; MS2, MS1 + modified BMI (\>23kg/m^2^); MS3, WHO definition modified with respect to WHR and BMI; BMI, body mass index; WC, waist circumference; WHR, waist--hip ratio.

Age and sex adjusted correlations of each MS component criteria among diabetic subjects in MS1 and MS3 groups are provided in [Table 2](#tbl2){ref-type="table"}. Insulin resistance is a mandatory criterion for the designation of MS accorded by MS3. Hence, in order to analyze comparable groups, only diabetics in the MS1 category were considered for analysis. TG, HDL-C, systolic blood pressure (SBP) and diastolic blood pressure (DBP) showed significant correlation between the two groups whereas WC did not correlate with either WHR or BMI. HTN implies already diagnosed hypertensive individuals who are on medication.

###### 

Correlation of MS traits in diabetic subjects between MS1 and MS3 groups

  MS1[\*](#tf2-1){ref-type="table-fn"} / MS3[\#](#tf2-2){ref-type="table-fn"}   N     p value   Mean ± SD
  ----------------------------------------------------------------------------- ----- --------- ----------------
  WC1 (cm)                                                                      767             92.87 ± 9.6
  WHR 3                                                                         767             0.93 ± 0.08
  BMI 3 (kg/m^2^)                                                               770             26.97 ± 4.5
  WC 1/WHR 3                                                                    761   NS        
  WC 1/BMI 3                                                                    764   NS        
  TG 1(mg/dl)                                                                   780             167.03 ± 83.56
  TG 3                                                                          780             167.48 ± 84.67
  TG 1/TG 3                                                                     774   0.000     
  HDL 1                                                                         780             40.01 ± 9.2
  HDL 3                                                                         780             40.02 ± 9.6
  HDL1/HDL 3                                                                    774   0.000     
  SBP1 (mm/Hg)                                                                  776             129.07 ± 16.84
  SBP 3                                                                         776             129.16 ± 17.13
  SBP1/SBP 3                                                                    770   0.003     
  DBP1 (mm/Hg)                                                                  776             82.10 ± 8.88
  DBP 3                                                                         776             83.24 ± 9.02
  DBP1/DBP 3                                                                    770   0.014     
  HTN 1/HTN 3                                                                   774   0.026     

**Notes:** Suffix 1 in each variable pertains to the trait in MS1 group;

Suffix 3 in each variable pertains to the trait in MS 3 group;

**Abbreviations:** WC, waist circumference; WHR, waist--hip ratio; BMI, body mass index; TG, triglyceride; HDL, high-density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood pressure; HTN, hypertension.

Amongst males, MS prevalence increased proportionately after 30 years of age in all the definitions to reach a maximum in the 50--59 age group ([Figure 1A](#fig1){ref-type="fig"}). MS prevalence reduced after 60 yrs of age that approximated to the levels prevalent in the 18--29 age group. MSI and MS2 identified higher number of younger people with MS (30--39 yrs) compared with the WHO and MS3 definitions. Amongst females, MS prevalence started to increase later than in the males (40 yrs onwards) and continued to remain high beyond 60 yrs of age, in contrast to our observation in males. Maximum prevalence was in the 50--59 age group ([Figure 1B](#fig1){ref-type="fig"}). Overall, the WHO and MS3 definitions diagnosed more males while the IDF criteria diagnosed more number of females with metabolic syndrome.

![**A** Prevalence of MS in males across different age groups according to various MS definition criteria. **B** MS prevalence in females. Also included is data on IARS cohort.](vhrm0401-189-01){#fig1}

MS, NIDDM, and CVD
------------------

Seven hundred and seventy six individuals (33.5%) in the IARS cohort had cardiovascular disease (CVD) by the time of their recruitment, while noninsulin-dependent diabetes mellitus (NIDDM) was present in 1048 (45.3%) subjects. 68.4% of subjects in the MS2 group were diabetic and had CVD compared with 30.3% of nondiabetics who had CVD. Only 17.2% of CVD affected people in our cohort were not diagnosed to have MS by the MS2 criteria. The mean ages of all CVD affected subjects either with or without MS2 and/or NIDDM was very similar and were as follows: 57 ± 8 years (CVD + MS2 + NIDDM), 54.7 ± 9 years (CVD + MS2 - NIDDM) and 55 ± 11 years (CVD - MS2 - NIDDM) (MS2 implies people diagnosed with MS as per MS2 definition). In comparison, MS3 also diagnosed a high proportion of people who had both CVD and MS and their mean age was 57.2 ± 8 years. The MS2, MS3 and IDF criteria were able to diagnose MS in people without CVD in their fourth decade of life (MS2 45.8 ± 12.7 years; MS3 47.6 ± 12.5 years; 45.57 ± 14.72).

Comparison of component risk factor for MS such as age, SBP, and DBP (p = 0.000), HTN, diabetes mellitus (DM), CVD (p \< 0.001), glucose fasting blood sugar (GFBS), WC, and BMI (p = 0.000) were significantly higher in the MS group and continued to remain significant after age and sex adjustment when compared with the non-MS group ([Table 3](#tbl3){ref-type="table"}). Results obtained from GEE showed similarity up to the third decimal place as compared to routine tests such as Chi-square for discrete variables and T-test, ANOVA, and binary logistic regression for continuous variables between MS and non-MS subjects implying that family relationship is not a confounding factor in this study.

###### 

Frequency and mean differences in cardiovascular risk factors between metabolic syndrome (MS)[\*](#tf3-1){ref-type="table-fn"} and non-MS group

  Risk factor         MS            Non-MS           GEE                            
  ------------------- ------------- ---------------- ------------- ---------------- -----------
  **Gender - male**   787 (59.04)                    567 (57.74)                    0.536
  **Female**          546 (40.96)                    415 (42.26)                    
  **Age**             1324 (99.8)   50.23 ± 12.25    976 (100)     39.24 ± 15.41    **0.000**
  **DM**              455 (34.21)                    54 (5.53)                      **0.000**
  **HTN**             579 (43.47)                    105 (10.74)                    **0.000**
  **SBP**             1327 (100)    128.69 ± 16.56   976 (100)     117.57 ± 12.75   **0.000**
  **DBP**             1327(100)     83.59 ± 8.9      976 (100)     77.9 ± 8.14      **0.000**
  **GFBS**            893 (67.3)    138.21 ± 56.83   658 (67.4)    103.01 ± 26.86   **0.000**
  **Smokers**         178 (18.22)                    308 (23.2)                     **0.004**
  **CVD**             578 (43.36)                    198 (20.14)                    **0.000**
  **WC**              1319 (99.4)   92.16 ± 9.61     974 (99.8)    82.88 ± 11.32    **0.000**
  **BMI**             1327 (100)    27.17 ± 4.28     974 (99.8)    23.74 ± 4.22     **0.000**

**Note:** MS refers to modified MS2 definition (Modified ATP-III definition).

**Abbreviations:** DM, diabetes mellitus; HTN, hypertension; SBP, systolic blood pressure; DBP, diastolic blood pressure; GFBS, CVD, cardiovascular disease; WC, waist circumference; BMI, body mass index.

Monocomponent analysis of MS traits across gender showed that HDL-C and BMI were significant contributors in males (N = 562, 71.4%; N = 676, 85.9%) and females (N = 474, 86.81%; N = 485, 88.8%) respectively. WC was more significant among females in MS2 (N = 480; 87.91%) group while WHR (N = 468, 91.8%) showed significant contribution in males as per the MS3 definition, thus indicating the influence of the gynecoid/android pelvis on WHR measures ([Figure 2](#fig2){ref-type="fig"}).

![The percent contribution of individual components used in the definition of MS among males and females.](vhrm0401-189-02){#fig2}

Discussion
==========

Distinct clinical features and metabolic predispositions are frequently noted in people with abdominal adiposity, insulin resistance, dyslipidemia, and HTN. To simplify the recognition of such a clustering, the WHO laid down definitive criteria ([@b27]), followed by the MS definition of NCEP--ATP-III ([@b20]) and IDF ([@b1]). The Center for Disease Control and Prevention and US Department of Health and Human Services have attributed a specific code to "dysmetabolic syndrome" (ICD \#277.7) ([@b6]) in the 9th revision in clinical classification, thus bestowing it with an implicative dignity.

Asian Indians are a high-risk population with respect to diabetes mellitus and CVD and the numbers are consistently on the rise ([@b9]; [@b8]). It has long been doubted that the above standard definitions of MS under represents its prevalence in the Asian Indian community, thereby delaying the commencement of definite preventive and therapeutic efforts in many individuals. The results of various studies have appreciated ethnic variation in clinical measures and disease outcomes in different populations ([@b3]; [@b25]). Part of the problem lies in the cutoffs for obesity as defined by the WHO and ATP-III, which are not valid for Asian Indians. This population is of smaller build, has high insulin resistance and a dysmetabolic adipocyte milieu at considerably lower BMI and abdominal adiposity as identified by a large WC ([@b7]). In the wake of ongoing debate and a lack of consensus, the WHO recognized the need for population specific cutoff definitions in order to make the diagnosis of MS more precise and modified the BMI cutoff in Asians ([@b28]). Also, the IDF ([@b1]) published consensus cutoff for WC that are more ethnic-specific, based on the Chinese, Malay, and Asian Indian populations. In the present study, three candidate definitions were devised for MS by substituting the above modified cutoffs for BMI and WC, as also the WHR in the ATP-III and WHO definitions while IDF criteria was independently assessed in this study. The various definitions were applied to a cohort with high-risk for CAD where all participants had a family history of premature onset of CAD. MS prevalence was higher in our cohort in comparison to other studies. At baseline, ATP-III labeled a significantly higher proportion of people with MS when compared with the WHO criteria. A consistent gain in MS diagnosis was achieved by applying the modified definitions over the standard ones. Maximum gain was obtained in the MS2 group as defined by applying modified WC and BMI over and above the MS1 definition, which used only a modification in WC in its criteria. A comparable finding was reported using modified ATP-III criteria for anthropometry, which included skin fold thickness measurements in their candidate definition ([@b19]). The IDF proposes that central obesity is an essential component of MS, while the American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI) opines that it is an optional component similar to the other MS factors. Also, the IDF supports a modified cut off in impaired fasting glucose (IFG) levels of ≥100 mg/dL as compared with ≥110 mg/DL set by other criteria. [@b17] support the AHA/NHLBI proposal in their study on risk of ischemic heart disease (IHD) risk among healthy Asians.

Distribution of MS across various age groups showed a gradual increase in prevalence with advancing age in both males and females in our cohort with maximum prevalence in the 50--59 age group. Distribution of MS prevalence was similar across age groups in MS1, MS2, and IDF categories. [@b25] reported a similar trend in prevalence. It is of interest to note that our study population was recruited through probands with premature CAD and the most vulnerable age group for manifestation of CAD was around the same time as the peak prevalence of MS in this study, which was around 51.75 ± 8.62 years. In this context, early detection of MS would be of immense importance to deploy prophylactic measures against component risk factors of MS. The modified ATP-III criteria \[MS1 and MS2\] were able to identify greater number of young people with MS \[30--39 yrs\] than the WHO criteria. Hence the above modifications do indicate their ability to identify the 'high-risk subjects' much earlier.

The NCEP definition is more flexible as it can diagnose MS even in the absence of glucose intolerance, which in itself is a predisposition to dysmetabolic dyslipidemia, an obesity phenotype and a pro-inflammatory status. The WHO criteria, on the other hand, mandate the presence of diabetes with the inclusion of microalbuminuria, which is not only a marker for renal disease, but also for CVD. By the time most patients receive a diagnosis of diabetes, they are more than likely to have developed micro- or macro-vascular disease ([@b9]). It can thus be expected that a greater proportion of the patients will have CVD, if MS is determined based on the WHO guidelines. This is reflected by a significant risk of development / progression of carotid atherosclerosis as noted in the prospective Bruneck study ([@b5]). Thus, there is a bias in prevalence in relation to this end point. In the IARS cohort, 68.4% of the CVD affected were diabetic. Employing the MS2 and MS3 criteria, those with MS but without CVD were identified by the mid-forties, while CVD appeared to be incident a decade later in our cohort. Also, MS2 was successful in identifying 82.8% of CVD cases. A similar observation was made in the 4S and the AFCAPS-TEXCAPS studies that estimated the prospective long-term relative risks of major cardiac events associated with MS after exclusion of DM ([@b10]).

In order to analyze the association of various phenotypes with MS, identification and selection of the best-suited definition was imperative for this study. To this end, it was hypothesized that any of the component factors that did not correlate between the candidate definitions was actually responsible for the gain that was observed in the MS diagnosis. Applying Pearson correlation to component factors of MS1 and MS3, all factors apart from the markers of adiposity, namely WC, WHR, and BMI, showed significant correlation ([Table 2](#tbl2){ref-type="table"}) thus implying that only those factors that were modified were responsible for the enhanced 'pick-up' rate. MS2 was therefore selected for further analysis in lieu of the maximum gain achieved in diagnosing MS.

Subjects with MS were on an average ten years older than those without the syndrome. Significantly larger number of people with MS were hypertensive and diabetic with higher anthropometric parameters and incidence of CVD when compared with those without MS. BMI showed correlation with WC but not with WHR, which indicates that WC and BMI may be better predictors of MS when compared with WHR in Asian Indians. [@b16] found similar correlation between WC and BMI and suggest that WC is a better marker of abdominal obesity than WHR.

The present study and previous related investigations suggest many opportunities to prevent and retard the progression of CVD in this high-risk group, such as weight loss, dietary and lifestyle modifications ([@b8]). This, in turn, would help to some extent in delaying the downstream progression into insulin resistance, hypertension and dyslipidemia. Also, control of conventional CVD risks is more effective when they are detected and arrested at an early developmental stage.

On the basis of this study and considering the prevalent socio-economic scenario in developing countries like India where limited resources are available to health providers and seekers alike, we would recommend the anthropometric evaluation of Asian Indians as a primary screening technique to identify metabolic syndrome. Only people with abnormal anthropometry could be subsequently subjected to various laboratory assays for confirmation of diagnosis of metabolic syndrome. To this effect we found that by applying lowered cutoff for BMI and WC criteria alone, about 30% of the cases in the MS2 category missed MS diagnosis underlining the importance of abnormal anthropometry in the identification of potential 'high-risk' MS subjects among Asian Indians.

In conclusion, prevalence of MS varies amongst ethnic groups. Asian Indians are high at risk for CVD, diabetes, and their predispositions. The criteria for defining MS in adult Asian Indians needs to be reassessed. Inclusion of modified cut-offs of WC, BMI in the ATP-III definition, and WHR in the WHO definition yielded higher rates of MS identification in our study. WC and BMI define MS better, while WC is a preferable marker of abdominal adiposity. However, these findings need further validation.
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